Phase 4 N=395 Nephropathy In Type 2 Diabetes and Cardio-renal Events
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 2 N=78 N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Diabetic Nephropathy · Proteinuria · Oxidative Stress
Primary: Change From Baseline in Urinary Albumin Excretion — 50.5; -28.13; -4.5; 96.6 mg/g
Phase 2 N=60 Study of LY3016859 in Participants With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449
Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Phase 4 N=34 Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Phase 2 N=256 A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathies
Primary: Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12 — 195.130; 182.378; 9.072; -6.539 mg/mmol — p=0.9889
Phase 2 N=36 Losartan to Reverse Sickle Nephropathy
Nephropathy · Sickle Cell Anemia
Primary: Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline — 1; 7; 5 Participants
Phase 4 N=21 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI — 22.04 1/ms
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 2 N=46 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
IgA Nephropathy
Primary: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 — 0.85; 0.80; 0.76; 0.69 Ratio to baseline…
N/A N=23,357 A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2
N/A N=58 UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
Idiopathic Nephrotic Syndrome
Primary: Number of Participants Reporting Medication Adherence — 25; 21; 19; 18 Participants
Phase 4 N=44 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Diabetic Nephropathies
Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min
Phase 3 N=35 DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Diabetic Peripheral Neuropathic Pain · Post-herpetic Neuralgia
Primary: Change From Baseline in Average Daily Pain Score (ADPS) at Each Week — -0.14; -0.20; -0.37; -0.50 units on a scale
Phase 2 N=156 A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants
Phase 2 N=226 A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathy
Primary: Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — 13.27; 5.02 percent (%)
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
Phase 3 N=20 The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic Kidney Disease
Primary: MCP-1:Creatinine Ratio in Urine — 27.9; 24.3 ng/mmol
Phase 3 N=170 Renoprotection in Early Diabetic Nephropathy in Pima Indians
Diabetic Nephropathy
Primary: Number of Participants With Decline in GFR — 2; 2; 1; 4 participants
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Phase 3 N=308 Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104 — 18.2; 29.5 Percentage of Participants
Phase 3 N=61 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
Phase 3 N=6,609 EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Chronic Kidney Disease
Primary: Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated') — 8.96; 6.85 patients with events/100 pt-yrs at…
Phase 4 N=84 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
SLE · Lupus Nephritis · SGLT2 Inhibitors
Primary: Effect of Dapagliflozin Compared to Placebo on Renal Function After One Year — 128; 114; 115.7; 100.3 mL/min/1.73 m²
Phase 2 N=21 Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
Lupus Nephritis
Primary: Complete and Partial Response Rate — 55 Percentage of participants
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants